The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.
The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.
复制标题
DOI:
10.1371/journal.pgen.1002148
复制
发表时间:
2011-07
期刊:
影响因子:
4.5
通讯作者:
Takeda S
中科院分区:
文献类型:
--
作者:
Qing Y;Yamazoe M;Hirota K;Dejsuphong D;Sakai W;Yamamoto KN;Bishop DK;Wu X;Takeda S
RAD51 recombinase polymerizes at the site of double-strand breaks (DSBs) where it performs DSB repair. The loss of RAD51 causes extensive chromosomal breaks, leading to apoptosis. The polymerization of RAD51 is regulated by a number of RAD51 mediators, such as BRCA1, BRCA2, RAD52, SFR1, SWS1, and the five RAD51 paralogs, including XRCC3. We here show that brca2-null mutant cells were able to proliferate, indicating that RAD51 can perform DSB repair in the absence of BRCA2. We disrupted the BRCA1, RAD52, SFR1, SWS1, and XRCC3 genes in the brca2-null cells. All the resulting double-mutant cells displayed a phenotype that was very similar to that of the brca2-null cells. We suggest that BRCA2 might thus serve as a platform to recruit various RAD51 mediators at the appropriate position at the DNA–damage site. Mutations in BRCA1 and BRCA2 predispose hereditary breast and ovarian cancer. Such mutations sensitize to chemotherapeutic agents, including camptothecin, cisplatin, and poly(ADP-ribose) polymerase (PARP) inhibitor, since RAD51 mediators including both BRCA proteins promote repair of DNA lesions induced by these drugs. Little is known of the functional relationships among RAD51, BRCA2, and other RAD51 mediators, because no brca2-null cells were available. Furthermore, the phenotype of sws1 mutants has not been documented. We here disrupted every known RAD51 mediator and analyzed the phenotype of the resulting mutants in both BRCA2-deficient and -proficient backgrounds. The understanding of the function of individual RAD51 mediators and their functional interactions will contribute to the accurate prediction of anti-cancer therapy efficacy.
登录
查看更多内容
DOI:
10.1056/nejmra0809889
发表时间:
2010-05-20
期刊:
The New England journal of medicine
影响因子:
--
作者:
D'Andrea AD
通讯作者:
D'Andrea AD
影响因子:
30.8
作者:
Connor, F;Bertwistle, D;Ashworth, A
通讯作者:
Ashworth, A
影响因子:
4.8
作者:
Fukushima, T;Takata, M;Takeda, S
通讯作者:
Takeda, S
影响因子:
16
作者:
Kawamoto, T;Araki, K;Takeda, S
通讯作者:
Takeda, S
影响因子:
4.8
作者:
Bhattacharyya, A;Ear, US;Bishop, DK
通讯作者:
Bishop, DK